<DOC>
	<DOCNO>NCT02493036</DOCNO>
	<brief_summary>A Single-Dose , Open-Label , Extension Study Evaluate Sustainability Effects SYN-010 Patients Irritable Bowel Syndrome Constipation</brief_summary>
	<brief_title>A Single-Dose , Open-Label , Study Evaluate Sustainability Effects SYN-010 Patients With IBS-C</brief_title>
	<detailed_description>This Phase 2 , multi-center , open-label study . Up sixty subject irritable bowel syndrome constipation age 18 65 , inclusive , enrol . Subjects must complete previous SB-2-010-001 study . The entire duration study may 57 day ( enrollment post end-of-study [ EOS ] visit telephone call ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Subject complete Study SB2010001 . Subject must willing abstain discontinue use laxatives prescription overthecounter medication supplement intend treat constipation time Screening end study , except permit protocol . Subject must agree refrain make lifestyle change may affect IBSC symptoms time Screening end study . Subject take IBS treatment ( prescription overthecounter ) , proton pump inhibitor , laxative , antibiotic . Subject complete Study SB2010001 7 day elapse since subject 's last dose study drug study . Subject report loose ( mushy ) watery stool ( Bristol Stool Form Scale [ BSFS ] score 6 7 ) absence laxative , BSFS score 6 1 spontaneous bowel movement ( SBM ) BSFS score 7 SBM last 7 day diary reporting Study SB2010001 . Subject abnormal laboratory result , electrocardiogram ( ECG ) finding , physical examination finding deem clinically significant investigator Study SB2010001 EndofStudy Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>